Intercell Update On Technology Partnerships: Intercell Outlicenses Group B Streptococcus Vaccine
Intercell announced that the Company has transferred on an exclusive basis its pre-clinical Group B Streptococcus (GBS) vaccine program to Novartis. At the same time Intercell has kept and received co-exclusive rights for the development of therapeutic antibodies against Group B Streptococcus and has in-licensed additional rights on GBS antibodies from Novartis.
More: continued here
Filed under: Immune System / Vaccines on January 4th, 2009